Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection

A. Andriulli, I. De Sio, F. Brunello, A. Salmi, L. Solmi, D. Facciorusso, E. Caturelli, F. Perri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Once small (10 to ≤20 mm (n = 142, group B) and >20 to ≤30 mm (n = 272, group C). Overall and tumour-free survivals were estimated by Kaplan-Meier method. Results: In groups A, B and C, mean follow-up was 33 ± 26, 34 ± 22 and 35 ± 25 months (P = 0.89), mean survival time was 63 ± 54, 57 ± 48 and 62 ± 66 months (P = 0.69) and mean tumour-free survival was 44 ± 47, 46 ± 58 and 41 ± 68 months (P = 0.51), respectively. When patients were sorted by Child status, mean survival time was 76 ± 82 and 38 ± 29 months in Child A and B (P <0.0001). Conclusions: The comparable survival of percutaneous alcohol injection-treated patients with single, early hepatocellular carcinoma sorted by nodular size supports the European Association for the Study of the Liver 'wait-and-see' policy for patients with lesions

Original languageEnglish
Pages (from-to)1329-1335
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume23
Issue number9
DOIs
Publication statusPublished - May 2006

Fingerprint

Hepatocellular Carcinoma
Alcohols
Injections
Survival
Survival Rate
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection. / Andriulli, A.; De Sio, I.; Brunello, F.; Salmi, A.; Solmi, L.; Facciorusso, D.; Caturelli, E.; Perri, F.

In: Alimentary Pharmacology and Therapeutics, Vol. 23, No. 9, 05.2006, p. 1329-1335.

Research output: Contribution to journalArticle

Andriulli, A. ; De Sio, I. ; Brunello, F. ; Salmi, A. ; Solmi, L. ; Facciorusso, D. ; Caturelli, E. ; Perri, F. / Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection. In: Alimentary Pharmacology and Therapeutics. 2006 ; Vol. 23, No. 9. pp. 1329-1335.
@article{8bbd2c114459432087ec98ed86a0c8d8,
title = "Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection",
abstract = "Background: Once small (10 to ≤20 mm (n = 142, group B) and >20 to ≤30 mm (n = 272, group C). Overall and tumour-free survivals were estimated by Kaplan-Meier method. Results: In groups A, B and C, mean follow-up was 33 ± 26, 34 ± 22 and 35 ± 25 months (P = 0.89), mean survival time was 63 ± 54, 57 ± 48 and 62 ± 66 months (P = 0.69) and mean tumour-free survival was 44 ± 47, 46 ± 58 and 41 ± 68 months (P = 0.51), respectively. When patients were sorted by Child status, mean survival time was 76 ± 82 and 38 ± 29 months in Child A and B (P <0.0001). Conclusions: The comparable survival of percutaneous alcohol injection-treated patients with single, early hepatocellular carcinoma sorted by nodular size supports the European Association for the Study of the Liver 'wait-and-see' policy for patients with lesions",
author = "A. Andriulli and {De Sio}, I. and F. Brunello and A. Salmi and L. Solmi and D. Facciorusso and E. Caturelli and F. Perri",
year = "2006",
month = "5",
doi = "10.1111/j.1365-2036.2006.02901.x",
language = "English",
volume = "23",
pages = "1329--1335",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection

AU - Andriulli, A.

AU - De Sio, I.

AU - Brunello, F.

AU - Salmi, A.

AU - Solmi, L.

AU - Facciorusso, D.

AU - Caturelli, E.

AU - Perri, F.

PY - 2006/5

Y1 - 2006/5

N2 - Background: Once small (10 to ≤20 mm (n = 142, group B) and >20 to ≤30 mm (n = 272, group C). Overall and tumour-free survivals were estimated by Kaplan-Meier method. Results: In groups A, B and C, mean follow-up was 33 ± 26, 34 ± 22 and 35 ± 25 months (P = 0.89), mean survival time was 63 ± 54, 57 ± 48 and 62 ± 66 months (P = 0.69) and mean tumour-free survival was 44 ± 47, 46 ± 58 and 41 ± 68 months (P = 0.51), respectively. When patients were sorted by Child status, mean survival time was 76 ± 82 and 38 ± 29 months in Child A and B (P <0.0001). Conclusions: The comparable survival of percutaneous alcohol injection-treated patients with single, early hepatocellular carcinoma sorted by nodular size supports the European Association for the Study of the Liver 'wait-and-see' policy for patients with lesions

AB - Background: Once small (10 to ≤20 mm (n = 142, group B) and >20 to ≤30 mm (n = 272, group C). Overall and tumour-free survivals were estimated by Kaplan-Meier method. Results: In groups A, B and C, mean follow-up was 33 ± 26, 34 ± 22 and 35 ± 25 months (P = 0.89), mean survival time was 63 ± 54, 57 ± 48 and 62 ± 66 months (P = 0.69) and mean tumour-free survival was 44 ± 47, 46 ± 58 and 41 ± 68 months (P = 0.51), respectively. When patients were sorted by Child status, mean survival time was 76 ± 82 and 38 ± 29 months in Child A and B (P <0.0001). Conclusions: The comparable survival of percutaneous alcohol injection-treated patients with single, early hepatocellular carcinoma sorted by nodular size supports the European Association for the Study of the Liver 'wait-and-see' policy for patients with lesions

UR - http://www.scopus.com/inward/record.url?scp=33645710044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645710044&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.02901.x

DO - 10.1111/j.1365-2036.2006.02901.x

M3 - Article

C2 - 16629938

AN - SCOPUS:33645710044

VL - 23

SP - 1329

EP - 1335

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -